Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership (Q44167851)

30 November 2017

0 references

Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership (English)

1 reference

30 November 2017

Robert Ilaria

1

1 reference

30 November 2017

1 November 2002

1 reference

30 November 2017

1 reference

30 November 2017

26

1 reference

30 November 2017

11

1 reference

30 November 2017

971-973

1 reference

Acute leukaemia in bcr/abl transgenic mice

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Transgenic systems for in vivo mutation analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Role for c-Abl tyrosine kinase in growth arrest response to DNA damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Interaction between ATM protein and c-Abl in response to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Regulation of Rad51 function by c-Abl in response to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Regulation of cell death by the Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900180-1

7 January 2021

10.1016/S0145-2126(01)00180-1

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12363461